We selected to further study the importance of DYRK1A for KMT2A-R ALL as it met the following three criteria: (1) Growth inhibition upon DYRK1A targeting was stronger in KMT2A-R leukemic cells as in non-KMT2A-R ALL cells, (2) DYRK1A is not a common essential gene assessed via the Cancer Dependency MAP, and (3) DYRK1A has not been studied specifically in KMT2A-R ALL. This evidence concerns the gene DYRK1A and acute lymphoblastic leukemia.